EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mesenchymal Stem Cells as Potential Therapeutics for Organ Fibrosis

Marina Gazdic Jankovic, Dragica Pavlovic, Zeljko Ivosevic, Biljana Ljujic

Future Pharmacology · 02.05.2026 · 6 (2) · 27

DOI: 10.3390/futurepharmacol6020027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 02.05.2026. Verfasst von Marina Gazdic Jankovic und 3 weiteren Autor:innen. Die Arbeit nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Science and Technological Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deposition of fibrous connective tissue within the extracellular matrix is initially an adaptive and reversible wound-healing process. However, persistent dysregulation of fibrotic signaling pathways induces irreversible cellular dysfunction, tissue degeneration and organ failure. Despite the high mortality rate associated with fibrotic diseases, there are very limited approved anti-fibrotic treatments and there is no therapeutic drug effective enough to completely invert the fibrotic process. Accordingly, new therapeutic agents that will attenuate ongoing fibrosis and, at the same time, promote regeneration of injured tissue are urgently needed. The search for new therapies has been revolutionized by recent advances in stem cell biology. Mesenchymal stem cells (MSCs) are promising candidates for the therapy of organ fibrosis because of their differentiation capabilities and immunomodulatory properties. The capacity of MSCs to suppress chronic inflammation and promote tissue repair and regeneration underlies their therapeutic effects in diseases such as liver cirrhosis, idiopathic pulmonary fibrosis, cardiac fibrosis, systemic sclerosis, and renal fibrosis. In this review, we summarize the present understanding of fibrotic disease, highlight promising research avenues, including MSC-based treatment options, and discuss the challenges involved with the clinical application of MSCs.

Förderung

  • Ministry of Education, Science and Technological Development

Zitieren

APA

Jankovic, M. G., Pavlovic, D., Ivosevic, Z., & Ljujic, B. (2026). Mesenchymal Stem Cells as Potential Therapeutics for Organ Fibrosis. Future Pharmacology, 6(2), 27. https://doi.org/10.3390/futurepharmacol6020027

Vancouver

Jankovic MG, Pavlovic D, Ivosevic Z, Ljujic B. Mesenchymal Stem Cells as Potential Therapeutics for Organ Fibrosis. Future Pharmacology. 2026;6(2):27. doi:10.3390/futurepharmacol6020027

BibTeX
@article{Jankovic2026,
  author = {Jankovic, Marina Gazdic and Pavlovic, Dragica and Ivosevic, Zeljko and Ljujic, Biljana},
  title = {Mesenchymal Stem Cells as Potential Therapeutics for Organ Fibrosis},
  journal = {Future Pharmacology},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {27},
  doi = {10.3390/futurepharmacol6020027}
}
Kostenlos starten →